Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling
Carla Danussi(The University of Texas MD Anderson Cancer Center), Jason T. Huse(The University of Texas MD Anderson Cancer Center), Prasanna Tamarapu Parthasarathy(Memorial Sloan Kettering Cancer Center), Adriana Heguy, Frederick F. Lang(The University of Texas MD Anderson Cancer Center), Pedro C. Silberman(Cornell University), C. Ryan Miller(University of North Carolina at Chapel Hill), Oliver Y. Tang(University of Pittsburgh), Promita Bose(Memorial Sloan Kettering Cancer Center), Chad J. Creighton(Baylor College of Medicine), Erik P. Sulman(NYU Langone Health), John S. Van Arnam(The University of Texas MD Anderson Cancer Center), Gregory J. Riggins(Unknown), Benjamin Deneen(Baylor College of Medicine), Kasthuri Kannan(New York University), Timothy A. Chan(Cleveland Clinic), Mark Vitucci(University of North Carolina at Chapel Hill), Yuxiang Wang(Memorial Sloan Kettering Cancer Center), David J. Picketts(Unknown)
Cited by 90
Related Papers
Mutations of the BRAF gene in human cancer
|Nature|2002|10.7k
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
|Neoplasia|2017|6.5k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k